Skip to main content

Omega Funds — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

79
Companies
$5.7B
Total invested
$96.1M
Avg. check
18
Industries
Biotechnology 20Health Care 14Medical 9Therapeutics 8Life Science 7Medical Device 6+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 79
Kestra Medical Technologies, Inc.
December 2025

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health Care · Kirkland$138.0M Post-IPO Equity
FoRx Therapeutics
December 2025

FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.

Biotechnology · Basel$50.0M Series A
Protego Biopharma
December 2025

Protego Biopharma is a biotechnology company that develops therapeutics that aim to correct diseases caused by protein misfolding.

Biopharma · San Diego$130.0M Series B
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
Caldera Therapeutics
January 2026

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

Biopharma · Cambridge$37.5M Series A
Alleviant Medical
January 2025

Alleviant Medical develops transcatheter technology designed to lift the clinical and economic burden of heart failure.

Biotechnology · Austin$90.0M Venture - Series Unknown
Kezar Life Sciences
October 2022

Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders

Health Care · South San Francisco$12.2M Post-IPO Equity
Rectify Pharmaceuticals
October 2021

Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.

Biotechnology · Cambridge$100.0M Series A
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post Ipo Debt
Spruce Biosciences
January 2026

Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.

Biopharma · South San FranciscoPost Ipo Equity
Alveus Therapeutics
January 2026

Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.

Biotechnology · Philadelphia$197.0M Series A
Spiro Medical
January 2026

Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment.

Biotechnology · Menlo Park$67.0M Series A
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post Ipo Equity
NRG Therapeutics
September 2025

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.

Biopharma · Cambridge$67.8M Series B
BBOT
August 2025

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

Biopharma · Palo Alto$261.0M Post Ipo Equity
ARTBIO
July 2025

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

Biotechnology · Cambridge$132.0M Series B
Trevi Therapeutics
June 2025

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$115.1M Post Ipo Equity
Senti Biosciences
May 2025

Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for cancer.

Biotechnology · South San Francisco$1.0M Grant
Antares Therapeutics
May 2025

Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.

Biopharma · Boston$177.0M Series A
Nuvation Bio
March 2025

Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.

Biotechnology · New York$150.0M Post Ipo Debt
Windward Bio
January 2025

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$200.0M Series A
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post Ipo Equity
Beta Bionics
November 2024

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$60.0M Series E
XII Medical
August 2024

XII Medical provides minimally invasive technology for obstructive sleep apnea.

Health Care · Union City$45.0M Series B

Where Omega Funds invests

Biotechnology20
Health Care14
Medical9
Therapeutics8
Life Science7
Medical Device6

About Omega Funds's portfolio

How many companies has Omega Funds invested in?

Omega Funds has invested in 79 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Omega Funds invest in?

Omega Funds's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 18 different industry categories.

What is Omega Funds's largest investment?

Among tracked funding rounds, Alumis received $345.1M in a Post Ipo Equity round. Omega Funds's total known invested capital is $5.7B.

What is the average investment size for Omega Funds?

Omega Funds's average investment size is $96.1M across its portfolio of 79 companies.

What are Omega Funds's most recent investments?

Recent Omega Funds portfolio additions include Kestra Medical Technologies, Inc., FoRx Therapeutics, Protego Biopharma, Alpine Immune Sciences, Caldera Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 79 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →